BioVie (BIVI) S-1 19 Jan 17 IPO registration Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Sep. 30, 2016
Document And Entity Information
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	1,580,149
Document Type	S1
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash	$ 8,745	$ 123,757		$ 267,481
Prepaid expenses		6,982		2,000
Total Current Assets	8,745	130,739		269,481
OTHER ASSETS:
Intangible Assets (Net of Amortization)	2,185,390	2,242,734
Goodwill	345,711	345,711
Total Fixed Assets	2,531,101	2,588,445
TOTAL ASSETS	2,539,846	2,719,184		269,481
CURRENT LIABILITIES:
Accounts Payable and accrued expenses	381,289	293,633		650
Loan Payable	8,000
Related Party Loan	10,000	10,000
Accrued Payroll	562,112	499,612		322,950
Total Current Liabilities	961,401	803,245		323,600
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 300,000,000 shares authorized; shares issued and 87,160,000 and 87,210,000 and 87,210,000 shares issued and outstanding at June 30, 2016 and 2015 and September 30, 2016, respectively	8,721	8,716		8,721
Additional paid in capital	2,925,403	2,911,560		514,485
Prepaid services paid for with common stock				(4,911)
Accumulated deficit	(1,355,679)	(1,004,337)		(572,414)
Total Stockholders' Equity	1,578,445	1,915,939		(54,119)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,539,846	$ 2,719,184		$ 269,481
LAT PARMA LLC
CURRENT ASSETS:
Cash			$ 5,347		$ 18,154
Loans to Partners			648		648
Total Current Assets			5,995		18,802
OTHER ASSETS:
TOTAL ASSETS			5,995		18,802
CURRENT LIABILITIES:
Related Party Loan			10,000		5,000
Total Current Liabilities			10,000		5,000
STOCKHOLDERS' EQUITY
Partner Capital Accounts			(4,005)		13,802
Total Stockholders' Equity			(4,005)		13,802
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY			$ 5,995		$ 18,802

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common Stock Shares Issued	87,210,000	87,160,000	87,210,000
Common stock, shares outstanding	87,210,000	87,160,000	87,210,000

STATEMENTS OF OPERATION

STATEMENTS OF OPERATION - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
REVENUE:
Sales
COST OF GOODS SOLD
GROSS MARGIN
OPERATING EXPENSES
Amortization	57,344		51,036
Research and development expenses	127,270		37,901		4,196
Payroll expenses	71,348	40,369	184,537		161,931
Professional fees	93,165	10,957	143,235		50,779
Selling, general and administrative expenses	2,226	3,301	15,319		16,471
TOTAL OPERATING EXPENSES	351,353	54,627	432,028		233,377
LOSS FROM OPERATIONS	(351,353)	(54,627)	(432,028)		(233,377)
OTHER EXPENSE (INCOME)
Interest Expense			81
Interest income	(11)	(61)	(186)		(369)
TOTAL OTHER EXPENSE (INCOME)	(11)	(61)	(105)		(369)
NET LOSS	$ (351,342)	$ (54,566)	$ (431,923)		$ (233,008)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	$ 0	$ 0	$ 0		$ 0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	87,205,550	87,210,000	87,198,875		87,210,000
LAT PARMA LLC
REVENUE:
Sales
COST OF GOODS SOLD
GROSS MARGIN
OPERATING EXPENSES
Research and development expenses						10,989
Professional fees				11,924		7,735
Bank Charges				526		329
Office Expenses						574
Conference Fee						1,080
Website Hosting				185		173
Telephone				187
Travel				5,821
Taxes & Licenses				250
Outside Services (See Note 5)				95,921
General and Administrative Expenses:				114,814		20,880
OTHER EXPENSE (INCOME)
Interest income				(7)
TOTAL OTHER EXPENSE (INCOME)				(7)
NET LOSS				(114,807)		(20,880)
Partnership Capital, Beginning				13,802		4,682
Partner Contributions (See Note 6)				97,000		30,000
Partnership Capital, ENDING				$ 4,005		$ 13,802

STATEMENT OF STOCKHOLDERS' DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Common Stock Shares	Capital in Excess of Par Value	Prepaid Services Paid with Common Sock	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2014	$ 8,721	$ 514,485	$ (12,411)	$ (339,406)	$ 171,389
Beginning Balance (in shares) at Jun. 30, 2014	87,210,000
Retirement of Shares
Amortization of prepaid services paid with common stock			7,500		7,500
Net Loss				(233,008)	(233,008)
Ending Balance at Jun. 30, 2015	$ 8,721	514,485	(4,911)	(572,414)	(54,119)
Ending Balance (in shares) at Jun. 30, 2015	87,210,000
Retirement of Shares	$ (5)				(5)
Retirement of Shares (in shares)	(39,869,999)
Shares Issued for Acquisition		2,397,075			2,397,075
Shares Issued for Acquisition (in shares)	39,820,000
Amortization of prepaid services paid with common stock			4,911		4,911
Net Loss				(431,923)	(431,923)
Ending Balance at Jun. 30, 2016	$ 8,716	2,911,560		(1,004,337)	1,915,939
Ending Balance (in shares) at Jun. 30, 2016	87,160,001
Option vested		8,848			8,848
Issuance of common stock for services	$ 5	4,995			5,000
Issuance of common stock for services, (in shares)	49,999
Net Loss				(351,342)	(351,342)
Ending Balance at Sep. 30, 2016	$ 8,721	$ 2,925,403		$ (1,355,679)	$ 1,578,445
Ending Balance (in shares) at Sep. 30, 2016	87,210,000

STATEMENT OF CASH FLOWS

STATEMENT OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (351,342)	$ (54,566)	$ (431,923)		$ (233,008)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Amortization of prepaid common stock for services		1,890	4,911		7,500
Amortization of intangible assets	57,344		51,036
Share based compensation expense	8,848		7,875
Changes in operating assets and liabilities:
Increase in prepaid expenses	6,982	1,500	(4,982)		(2,000)
Accounts Payable	87,656	8,842	42,790		650
Accrued Payroll	62,500	40,369	176,662		161,475
Net cash used by operating activities	(128,012)	(1,965)	(163,631)		(65,383)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired through the merger			9,912
Net cash used by investing activities			9,912
CASH FLOWS FROM FINANCING ACTIVITIES:
Retirement of common Stock			(5)
Proceeds from loan payable	8,000
Proceeds from issuance of common stock	5,000
Net cash provided by financing activities	13,000		(5)
Net decrease in cash	(115,012)	(1,965)	(143,724)		(65,383)
Cash, beginning of period	123,757	267,481	267,481		332,864
Cash, end of period	8,745	265,516	123,757		267,481
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for Income Tax
Non-cash investing activities
Fair value of assets acquired, net of cash acquired	2,283,858		2,283,858
Fair value of liabilities assumed	$ 260,193		$ 260,193
LAT PARMA LLC
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss				$ (114,807)		$ (20,880)
CASH FLOWS FROM FINANCING ACTIVITIES:
Partner Contributions				97,000		30,000
Loan from Partners				5,000
Net cash provided by financing activities				102,000		9,120
Net decrease in cash				(12,807)		9,120
Cash, beginning of period				18,154		9,034
Cash, end of period				$ 5,347		$ 18,154

Background Information

Background Information	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Background Information	1. Background Information BioVie Inc. (F/K/A NanoAntibiotics, Inc.) (the “Company”) is a development stage enterprise that was incorporated in the state of Nevada on April 10, 2013. The Company is engaged in the discovery, development and commercialization of a therapy targeting ascites due to liver cirrhosis. Ascites due to liver cirrhosis is a life-threatening condition affecting about 100,000 Americans and many times more worldwide. Our therapy BIV201 is based on a drug that’s approved in about 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients. The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. We currently own all development and marketing rights to our drug candidate, except as noted previously, the Company and PharmaIN have exchanged small (low single-digit) ownership rights to each other’s ascites drug development programs. The Company recently filed patent applications for its drug candidate in the US and Japan, as well as a PCT in Europe. We are currently completing the work necessary to file our investigational new drug (IND) application, and aim to commence clinical trials should the FDA approve our application. The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company’s business plan.	1. Background Information BioVie Inc. (F/K/A NanoAntibiotics, Inc.) (the “Company”) is a development stage enterprise that was incorporated in the state of Nevada on April 10, 2013. The Company is engaged in the discovery, development and commercialization of a therapy targeting ascites due to liver cirrhosis. Ascites due to liver cirrhosis is a life-threatening condition affecting about 100,000 Americans and many times more worldwide. Our therapy BIV201 is based on a drug that’s approved in about 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients. The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. We currently own all development and marketing rights to our drug candidate. The Company and PharmaIN have exchanged small (low single-digit) ownership rights to each other’s ascites drug development programs. The Company recently filed patent applications for its drug candidate in the US and Japan, as well as a PCT in Europe. We are currently completing the work necessary to file our investigational new drug (IND) application, and aim to commence clinical trials should the FDA approve our application. The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company’s business plan.
LAT PARMA LLC
Background Information			NOTE 1: NATURE OF OPERATIONS LAT Pharma LLC (“LAT Pharma” or “The Company”) was created in 2006 with the goal of inventing, developing, and commercializing a lifesaving new therapy for people afflicted with advanced liver disease and cirrhosis of the liver and its deadly complications. The company works to develop and commercialize a novel treatment for ascites. Approximately 60% of people with liver cirrhosis (more than 400,000 Americans and millions worldwide) will develop this poorly controlled and frequently fatal condition. Therefore, the company is working to design a new drug to become the first long-acting pain management for the chronic administration of ascites—and the only agent that targets its root cause: portal hypertension. Since the company’s inception, it has not incurred any revenue and only expenses while the company works to develop the treatment as such described. Therefore, the company has applied for a provisional U.S. patent for its work thus far, but has not yet applied for a permanent Patent.

Going Concern

Going Concern	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Notes to Financial Statements
Going Concern	2. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the three months ended September 30, 2016, the Company had a net loss of $351,342. As of September 30, 2016, the Company has not earned any revenues. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally from the sale of public equity securities. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.	2. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended June 30, 2016, the Company had a net loss of $431,923. As of June 30, 2016, the Company has not earned any revenues. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally from the sale of public equity securities. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Significant Accounting Policies	3. Significant Accounting Policies Unaudited Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our cash balances were fully insured at September 30, 2016. Financial Instruments The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $127,270 for research and development for the quarter ended September 30, 2016. Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company follows the provisions of FASB ASC 740-10 “ Uncertainty in Income Taxes Earnings (Loss) per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the quarter ended September 30, 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. Stock-based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). Fair Value Measurements In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “ Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2016. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll. Recent accounting pronouncements The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.	3. Significant Accounting Policies Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at June 30, 2016, and our interest bearing cash balances may exceed federally insured limits. Financial Instruments The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $37,901 and $4,196 for research and development for the years ended June 30, 2016 and 2015, respectively. Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company follows the provisions of FASB ASC 740-10 “ Uncertainty in Income Taxes Earnings (Loss) per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the year ended June 30, 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. Stock-based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). Fair Value Measurements In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “ Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll. Recent accounting pronouncements The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.
LAT PARMA LLC
Significant Accounting Policies			NOTE 2: BASIS OF ACCOUNTING The accompanying financial statements present financial results on the accrual basis of accounting required under generally accepted accounting principles. USE OF ESTIMATES The preparation of the company’s financial statements, conforming with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that can affect certain reported amounts and disclosures. Therefore, actual results could differ from those estimates.

Related Party Loan

Related Party Loan	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Related Party Loan	4. Related Party Loan LAT Pharma was given a zero-interest bearing loan by the company’s General Partner, Jonathan Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015. The total of $10,000 was outstanding when the Company merged with LAT Pharma. As of September 30 th	4. Related Party Loan LAT Pharma was given a zero-interest bearing loan by the company’s General Partner, Jonathan Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015. The total of $10,000 was outstanding when the Company merged with LAT Pharma. As of June 30 th
LAT PARMA LLC
Related Party Loan			NOTE 3: LOANS FROM PARTNERS LAT Pharma was given a zero-interest bearing loan by the company’s General Partner, Jonathan Adams in the amount of $5,000 in June 2013 that was repaid in January 2015. Thus, the ending balance of the loan at December 31, 2014 was $5,000. Jonathan then made a partner contribution of that same amount to the company in August 2015. In November 2015 he once again loaned the company $10,000 that was unpaid as of December 31, 2015.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies	5. Commitments and Contingencies Office Lease On January 1, 2014 the Company executed a lease agreement with Cummings Properties for the company’s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $357 ($4,284 annually for each of the five years, total aggregate of $21,420). Employment Agreements On April 11, 2016 the Company entered into employment agreement with CEO Jonathan Adams. The Company’s agreement provides for a three-year term with minimum annual base salary of $250,000 per year. Effective April 11, 2016, the (previous) CEO/CFO resigned.	5. Commitments and Contingencies Office Lease On January 1, 2014 the Company executed a lease agreement with Cummings Properties for the company’s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $357 ($4,284 annually for each of the five years, total aggregate of $21,420). Employment Agreements On April 11, 2016 the Company entered into an employment agreement with CEO Jonathan Adams. The Company’s agreement provides for a three-year term with minimum annual base salary of $250,000 per year. Effective April 11, 2016, the (previous) CEO/CFO resigned.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes Deferred taxes are recorded for all existing temporary differences in the Company’s assets and liabilities for income tax and financial reporting purposes. Due to the valuation allowance for deferred tax assets, as noted below, there were no net deferred tax benefit or expense for the quarter ended September 30, 2016. There is no current or deferred income tax expense or benefit allocated to continuing operations for the quarter ended September 30, 2016. The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference are as follows: September 30, 2016 June 30, 2016 Tax expense (benefit) at U.S. statutory rate $ (119,460 ) $ (146,889 ) State income tax expense (benefit), net of federal benefit (17,568 ) (21,659 ) Effect of non-deductible expenses Other Change in valuation allowance 137,028 168,548 $ — $ — The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at September 30, 2016 were as follows: Deferred tax assets (liability), noncurrent: Net operating loss $ 528,876 Valuation allowance (528,876 ) $ — Change in valuation allowance: Balance, June 30, 2016 $ 391,848 Increase in valuation allowance 137,028 Balance, September 30, 2016 528,876 Since management of the Company believes that it is more likely than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net deferred tax assets as of September 30, 2016. As of September 30, 2016, the Company had federal and state net operating loss carry-forwards totaling approximately $1,355,679 which begin expiring in 2022.	6. Income Taxes Deferred taxes are recorded for all existing temporary differences in the Company’s assets and liabilities for income tax and financial reporting purposes. Due to the valuation allowance for deferred tax assets, as noted below, there were no net deferred tax benefit or expense for the year ended June 30, 2016. There is no current or deferred income tax expense or benefit allocated to continuing operations for the year ended June 30, 2016. The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference are as follows: June 30, 2016 June 30, 2015 Tax expense (benefit) at US. statutory rate $ (146,889 ) $ (79,200 ) State income tax expense (benefit): net of federal benefit $ (21,659 ) $ (11,700 ) Effect of non-deductible expenses Other Change in valuation allowance $ 168,548 $ 90,900 $ — $ — The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at June 30, 2016 are as follows: Deferred tax assets (liability), noncurrent: Net operating loss $ 431,923 Valuation allowance (431,923 ) $ — Change in valuation allowance: Balance, June 30, 2015 $ 223,300 Increase in valuation allowance 168,548 Balance, June 30, 2016 391,848 Since management of the Company believes that it is more likely than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net deferred tax assets as of June 30, 2016. As of June 30, 2016, the Company had federal and state net operating loss carry-forwards totaling approximately $1,004,000 which begin expiring in 2022.

Purchase of LAT Pharma

Purchase of LAT Pharma	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Business Combinations [Abstract]
Purchase of LAT Pharma	7. Purchase of LAT Pharma On April 11, 2016, the Company entered into and consummated an Agreement and Plan of Merger (the “Merger Agreement”), with LAT Acquisition Corp., a Nevada corporation and wholly-owned subsidiary of the Company (“Acquisition”) and LAT Pharma, LLC an Illinois limited liability company (“LAT”). Pursuant to the terms of the Merger Agreement, Acquisition merged with and into LAT in a statutory triangular merger (the “Merger”) with LAT surviving as a wholly-owned subsidiary of the Company. As consideration for the Merger, the Company issued the interest holders of LAT (the “LAT Holders”) an aggregate of 39,820,000 shares of our Common Stock issued to the LAT Holders in accordance with their pro rata ownership of LAT membership interests prior to the Merger. Following the Merger, the Registrant will continue the development of LAT’s lead clinical therapeutic candidate Continuous low-dose Infusion (CI) Terlipressin. Immediately prior to the Merger, the Company had 87,210,000 shares of Common Stock issued and outstanding. In connection with the Merger, certain shareholders of the Company collectively agreed to retire and cancel an aggregate of 39,869,999 shares of Common Stock. Following the consummation of the Merger, the issuance of the Merger Shares of the 39,820,000 shares of Common Stock, the Company had 87,160,001 shares of Common Stock issued and outstanding and the LAT Holders beneficially own 39,820,000 shares or approximately forty-six percent (46%) of such issued and outstanding Common Stock. Under the purchase method of accounting, the transaction was valued for accounting purposes at $2,389,200, which was the estimated fair value of the consideration paid by the Company. The estimate was based on the consideration paid of 39,820,000 shares of common stock valued based on the closing price on 04/11/2016 of $0.06 per share. The assets and liabilities of LAT Pharma, Inc. were recorded at their respective fair values as of the closing date of the Merger Agreement, and the following table summarizes these values based on the balance sheet at April 11, 2016. $ 2,303,682 Assets Purchased 260,193 Liabilities Assumed 2,043,489 Net Assets Purchased 2,389,200 Purchase Price $ 345,711 Goodwill from Purchase Intangible asset detail $ 2,293,770 Intangible Intellectual Property 345,711 Goodwill $ 2,639,481 Intangible Asset from Purchase Under the 338(h)(10) election, all goodwill and intangibles related to the acquisition of LAT Pharma will be fully deductible for tax purposes. The intangible intellectual property is amortized over 10 years. September 2016 September 2015 Intangible Assets subject to Amortization $ 2,293,770 $ — Amortization Expense in current year $ 57,344 $ — Accumulated Amortization at year end $ 108,380 $ — The previous year amortization expense has been amortized for the period from April 11, 2016 to June 30, 2016. The estimated Amortization expense for each of the five succeeding fiscal years will be approximately $229,300 per year.	7. Purchase of LAT Pharma On April 11, 2016, the Company entered into and consummated an Agreement and Plan of Merger (the “Merger Agreement”), with LAT Acquisition Corp., a Nevada corporation and wholly-owned subsidiary of the Company (“Acquisition”) and LAT Pharma, LLC an Illinois limited liability company (“LAT”). Pursuant to the terms of the Merger Agreement, Acquisition merged with and into LAT in a statutory triangular merger (the “Merger”) with LAT surviving as a wholly-owned subsidiary of the Company. As consideration for the Merger, the Company issued the interest holders of LAT (the “LAT Holders”) an aggregate of 39,820,000 shares of our Common Stock issued to the LAT Holders in accordance with their pro rata ownership of LAT membership interests prior to the Merger. Following the Merger, the Registrant will continue the development of LAT’s lead clinical therapeutic candidate Continuous low-dose Infusion (CI) Terlipressin. Immediately prior to the Merger, the Company had 87,210,000 shares of Common Stock issued and outstanding. In connection with the Merger, certain shareholders of the Company collectively agreed to retire and cancel an aggregate of 39,869,999 shares of Common Stock. Following the consummation of the Merger, the issuance of the Merger Shares of the 39,820,000 shares of Common Stock, the Company had 87,160,001 shares of Common Stock issued and outstanding and the LAT Holders beneficially own 39,820,000 shares or approximately forty-six percent (46%) of such issued and outstanding Common Stock. Under the purchase method of accounting, the transaction was valued for accounting purposes at $2,389,200, which was the estimated fair value of the consideration paid by the Company. The estimate was based on the consideration paid of 39,820,000 shares of common stock valued based on the closing price on 04/11/2016 of $0.06 per share. The assets and liabilities of LAT Pharma, Inc. were recorded at their respective fair values as of the closing date of the Merger Agreement, and the following table summarizes these values based on the balance sheet at April 11, 2016. $ 2,303,682 Assets Purchased 260,193 Liabilities Assumed 2,043,489 Net Assets Purchased 2,389,200 Purchase Price $ 345,711 Goodwill from Purchase Intangible asset detail $ 2,293,770 Intangible Intellectual Property 345,711 Goodwill $ 2,639,481 Intangible Asset from Purchase Under the 338(h)(10) election, all goodwill and intangibles related to the acquisition of LAT Pharma will be fully deductible for tax purposes. The intangible intellectual property is amortized over 10 years. June 2016 June 2015 Intangible Assets subject to Amortization $ 2,293,770 $ — Amortization Expense in current year $ 51,036 $ — Accumulated Amortization at year end $ 51,036 $ — The current year amortization expense has been amortized for the period from April 11, 2016 to June 30,2016. The estimated Amortization expense for each of the five succeeding fiscal years will be approximately $229,300 per year.

Stock Options

Stock Options	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	8. Stock Options In connection with the employment agreement signed with the Chief Financial Officer on April 11, 2016, Jonathan Adams received options to acquire 3 million shares exercisable at $0.06 per share, the closing price on that date. These Options Group A shall become vested and exercisable (i) as to 1 million shares on April 11, 2017, (ii) as to 1 million shares on April 11, 2018, and (iii) as to 1 million shares on April 11, 2019. The fair market value of the stock options is estimated using the Black Scholes valuation model and the Company uses the following methods to determine its underlying assumptions: expected volatilities are based on the historical volatilities of 3 comparable companies of the daily closing price of their respective common stock; the expected term of options granted is based on the average time outstanding method; and the risk free interest rate is based on the US Treasury bonds issued with similar life terms to the expected life of the grant. The following key assumptions were used in the valuation model to value stock option grants for each respective period: Valuation Date 4/11/2016 4/11/2016 4/11/2016 Stock Price $ 0.06 $ 0.06 $ 0.06 Exercise Price $ 0.06 $ 0.06 $ 0.06 Term (expected term for options) 1.00 2.00 3.00 Volatility 56.49 % 58.45 % 97.82 % Annual Rate of Quarterly Dividends 0.00 % 0.00 % 0.00 % Discount Rate - Bond Equivalent Yield 0.53 % 0.70 % 0.85 % Call Option Value ($Millions) $ 0.01 $ 0.02 $ 0.04 Fair Value $ 13,467 $ 19,523 $ 36,489 Weighted Weighed- Average Aggregate Average Remaining Intrinsic Shares Exercise Contractual Value Options (Thousands) Price Term (Thousands) Outstanding at July 1, 2015 - - - - Granted 3,000 0.06 2 - Exercised - - - - Forfieted - - - - Outstanding at June 30, 2016 3,000 0.06 2 - Granted - - - - Exercised - - - - Forfieted - - - - Outstanding at September 30, 2016 3,000 0.06 2 - The compensation expense includes $8,848 related to the stock options described above.	8. Stock Options In connection with the employment agreement signed with the Chief Financial Officer on April 11, 2016, Jonathan Adams was granted options to acquire 3 million shares exercisable at $0.06 per share, the closing price on that date. These Options Group A shall become vested and exercisable (i) as to 1 million shares on April 11, 2017, (ii) as to 1 million shares on April 11, 2018, and (iii) as to 1 million shares on April 11, 2019. The fair market value of the stock options is estimated using the Black Scholes valuation model and the Company uses the following methods to determine its underlying assumptions: expected volatilities are based on the historical volatilities of 3 comparable companies of the daily closing price of their respective common stock; the expected term of options granted is based on the average time outstanding method; and the risk free interest rate is based on the US Treasury bonds issued with similar life terms to the expected life of the grant. The following key assumptions were used in the valuation model to value stock option grants for each respective period: Valuation Date 4/11/2016 4/11/2016 4/11/2016 Stock Price $ 0.06 $ 0.06 $ 0.06 Exercise Price $ 0.06 $ 0.06 $ 0.06 Term (expected term for options) 1.00 2.00 3.00 Volatility 56.49 % 58.45 % 97.82 % Annual Rate of Quarterly Dividends 0.00 % 0.00 % 0.00 % Discount Rate - Bond Equivalent Yield 0.53 % 0.70 % 0.85 % Call Option Value ($Millions) $ 0.01 $ 0.02 $ 0.04 Fair Value $ 13,467 $ 19,523 $ 36,489 Stock option transactions under the Company’s plans for the years ended June 30, 2016 is summarized below: Weighted Weighted- Average Aggregate Average Remaining Intrinsic Shares Exercise Contractual Value Options (Thousands) Price Term (Thousands) Outstanding at July 1, 2015 — — — — Granted 3,000 0.06 2 — Exercised — — — — Forfeited — — — — Outstanding at June 30, 2016 3,000 0.06 2 — The compensation expense includes $7,875 related to the stock options described above.

Loan Payable

Loan Payable	3 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Loan Payable	9. Loan Payable LAT Pharma was given a zero-interest bearing loan from Barrett Ehrlich for $8,000. Barrett Ehrlich made a payment to Hayden IR, LLC directly on behalf of LAT Pharma. As of September 30 th

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Event Subsequent to September 30, 2016, the Company sold 500,000 shares of common stock for 20 cents per share for total proceeds of $100,000.	9. Subsequent Events Subsequent to year end 49,999 shares were issued and sold by the Company for 10 cents per share.

LEGAL FEES

LEGAL FEES	12 Months Ended
	Dec. 31, 2015
LAT PARMA LLC
LEGAL FEES	NOTE 4: LEGAL FEES The company incurred an expense for legal fees in the amount of $7,735 for the calendar year ended December 31, 2014, and $11,924 for the calendar year ended December 31, 2015 for general legal advice and help with the provision patent application filing.

OUTSIDE SERVICES

OUTSIDE SERVICES	12 Months Ended
	Dec. 31, 2015
LAT PARMA LLC
OUTSIDE SERVICES	NOTE 5: OUTSIDE SERVICES For the year ended December 31, 2015 the company’s largest expense was Outside Services. This expense was for independent consultants that included physician experts, European orphan drug consultants, and contract research.

PARTNERSHIP CONTRIBUTIONS

PARTNERSHIP CONTRIBUTIONS	12 Months Ended
	Dec. 31, 2015
LAT PARMA LLC
PARTNERSHIP CONTRIBUTIONS	NOTE 6: PARTNERSHIP CONTRIBUTIONS As of December 31, 2014 the company had thirty-eight partners with a total contribution to the company of $430,300. Two partners owned nearly 20%. By December 31, 2015 the company recruited two additional partners increasing the total number to forty, and increased its contributions another $97,000, bringing the cumulative capital contributed to the partnership to $527,300.

Significant Accounting Polici20

Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash	Cash Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our cash balances were fully insured at September 30, 2016.	Cash Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at June 30, 2016, and our interest bearing cash balances may exceed federally insured limits.
Financial Instruments	Financial Instruments The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.	Financial Instruments The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.
Research and Development	Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $127,270 for research and development for the quarter ended September 30, 2016.	Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $37,901 and $4,196 for research and development for the years ended June 30, 2016 and 2015, respectively.
Income Taxes	Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company follows the provisions of FASB ASC 740-10 “ Uncertainty in Income Taxes	Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company follows the provisions of FASB ASC 740-10 “ Uncertainty in Income Taxes
Earnings (Loss) per Share	Earnings (Loss) per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the quarter ended September 30, 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.	Earnings (Loss) per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. For the year ended June 30, 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.
Stock-based Compensation	Stock-based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).	Stock-based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
Fair Value Measurements	Fair Value Measurements In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “ Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2016. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.	Fair Value Measurements In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “ Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.
Recent accounting pronouncements	Recent accounting pronouncements The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.	Recent accounting pronouncements The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Reconciliation of the federal statutory income tax rate to income tax expense expense	September 30, 2016 June 30, 2016 Tax expense (benefit) at U.S. statutory rate $ (119,460 ) $ (146,889 ) State income tax expense (benefit), net of federal benefit (17,568 ) (21,659 ) Effect of non-deductible expenses Other Change in valuation allowance 137,028 168,548 $ — $ —	June 30, 2016 June 30, 2015 Tax expense (benefit) at US. statutory rate $ (146,889 ) $ (79,200 ) State income tax expense (benefit): net of federal benefit $ (21,659 ) $ (11,700 ) Effect of non-deductible expenses Other Change in valuation allowance $ 168,548 $ 90,900 $ — $ —
Schedule of gross amounts of deferred tax assets and deferred tax liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at September 30, 2016 were as follows: Deferred tax assets (liability), noncurrent: Net operating loss $ 528,876 Valuation allowance (528,876 ) $ — Change in valuation allowance: Balance, June 30, 2016 $ 391,848 Increase in valuation allowance 137,028 Balance, September 30, 2016 528,876	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at June 30, 2016 are as follows: Deferred tax assets (liability), noncurrent: Net operating loss $ 431,923 Valuation allowance (431,923 ) $ — Change in valuation allowance: Balance, June 30, 2015 $ 223,300 Increase in valuation allowance 168,548 Balance, June 30, 2016 391,848

Purchase of LAT Pharma (Tables)

Purchase of LAT Pharma (Tables)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Purchase Of Lat Pharma Tables
Schedule of Assets and Liabilities of LAT Pharma, Inc.	The assets and liabilities of LAT Pharma, Inc. were recorded at their respective fair values as of the closing date of the Merger Agreement, and the following table summarizes these values based on the balance sheet at April 11, 2016. $ 2,303,682 Assets Purchased 260,193 Liabilities Assumed 2,043,489 Net Assets Purchased 2,389,200 Purchase Price $ 345,711 Goodwill from Purchase Intangible asset detail $ 2,293,770 Intangible Intellectual Property 345,711 Goodwill $ 2,639,481 Intangible Asset from Purchase The intangible intellectual property is amortized over 10 years. June 2016 June 2015 Intangible Assets subject to Amortization $ 2,293,770 $ — Amortization Expense in current year $ 51,036 $ — Accumulated Amortization at year end $ 51,036 $ —	The assets and liabilities of LAT Pharma, Inc. were recorded at their respective fair values as of the closing date of the Merger Agreement, and the following table summarizes these values based on the balance sheet at April 11, 2016. $ 2,303,682 Assets Purchased 260,193 Liabilities Assumed 2,043,489 Net Assets Purchased 2,389,200 Purchase Price $ 345,711 Goodwill from Purchase Intangible asset detail $ 2,293,770 Intangible Intellectual Property 345,711 Goodwill $ 2,639,481 Intangible Asset from Purchase The intangible intellectual property is amortized over 10 years. June 2016 June 2015 Intangible Assets subject to Amortization $ 2,293,770 $ — Amortization Expense in current year $ 51,036 $ — Accumulated Amortization at year end $ 51,036 $ —

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Stock Options Tables
Schedule of Stock option grants for each respective period	The following key assumptions were used in the valuation model to value stock option grants for each respective period: Valuation Date 4/11/2016 4/11/2016 4/11/2016 Stock Price $ 0.06 $ 0.06 $ 0.06 Exercise Price $ 0.06 $ 0.06 $ 0.06 Term (expected term for options) 1.00 2.00 3.00 Volatility 56.49 % 58.45 % 97.82 % Annual Rate of Quarterly Dividends 0.00 % 0.00 % 0.00 % Discount Rate - Bond Equivalent Yield 0.53 % 0.70 % 0.85 % Call Option Value ($Millions) $ 0.01 $ 0.02 $ 0.04 Fair Value $ 13,467 $ 19,523 $ 36,489 Stock option transactions under the Company’s plans for the years ended June 30, 2016 is summarized below: Weighted Weighted- Average Aggregate Average Remaining Intrinsic Shares Exercise Contractual Value Options (Thousands) Price Term (Thousands) Outstanding at July 1, 2015 — — — — Granted 3,000 0.06 2 — Exercised — — — — Forfeited — — — — Outstanding at June 30, 2016 3,000 0.06 2 —	The following key assumptions were used in the valuation model to value stock option grants for each respective period: Valuation Date 4/11/2016 4/11/2016 4/11/2016 Stock Price $ 0.06 $ 0.06 $ 0.06 Exercise Price $ 0.06 $ 0.06 $ 0.06 Term (expected term for options) 1.00 2.00 3.00 Volatility 56.49 % 58.45 % 97.82 % Annual Rate of Quarterly Dividends 0.00 % 0.00 % 0.00 % Discount Rate - Bond Equivalent Yield 0.53 % 0.70 % 0.85 % Call Option Value ($Millions) $ 0.01 $ 0.02 $ 0.04 Fair Value $ 13,467 $ 19,523 $ 36,489 Stock option transactions under the Company’s plans for the years ended June 30, 2016 is summarized below: Weighted Weighted- Average Aggregate Average Remaining Intrinsic Shares Exercise Contractual Value Options (Thousands) Price Term (Thousands) Outstanding at July 1, 2015 — — — — Granted 3,000 0.06 2 — Exercised — — — — Forfeited — — — — Outstanding at June 30, 2016 3,000 0.06 2 —

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Notes to Financial Statements
Net Loss	$ 351,342	$ 54,566	$ 431,923	$ 233,008

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended	60 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2018
Notes to Financial Statements
Lease rental	$ 357	$ 4,284	$ 21,420
Lease term (in years)	5 years

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Tax expense (benefit) at U.S. statutory rate	$ (119,460)	$ (146,889)	$ (79,200)
State income tax expense (benefit), net of federal benefit	(17,568)	(21,659)	(11,700)
Effect of non-deductible expenses
Other
Change in valuation allowance	137,028	168,548	90,900
Total

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets (liability)
Net operating loss	$ 528,876	$ 431,923
Valuation allowance	(528,876)	(391,848)	$ (223,300)
Total
Federal and State net operating loss carry-forwards	$ 1,355,679	$ 1,004,000

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Change in valuation allowance:
Beginning Balance	$ 391,848	$ 223,300
Increase in valuation allowance	137,028	168,548	$ 90,900
Ending Balance	$ 528,876	$ 391,848	$ 223,300

Purchase of LAT Pharma (Details

Purchase of LAT Pharma (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Apr. 11, 2016	Jun. 30, 2015
Goodwill	$ 345,711	$ 345,711
LAT Pharma, Inc. [Member]
Assets Purchased			$ 2,303,682
Liabilities Assumed			260,193
Net Assets Purchased			2,043,489
Purchase Price			2,389,200
Goodwill			345,711
Intangible Intellectual Property			2,293,770
Intangible Asset from Purchase			$ 2,639,481

Stock Options (Details)

Stock Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Stock Options Details
Option Outstanding at beginning of year	3,000
Option Granted		3,000
Option Exercised
Option Forfeited
Option Outstanding at end of year	3,000	3,000
Outstanding Weighted Average Exercise Price at the beginning	$ 0.06
Weighted Average Exercise Price, Granted		.06
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Outstanding Weighted Average Exercise Price at the end	$ 0.06	$ 0.06
Weighted Average Remaining Contractual Term	2 years	2 years